MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
CareDx, Inc Operating Income 2011-2025 | CDNA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income CareDx, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -203 M | -77.2 M | -29.7 M | -22.5 M | -24.5 M | -15.6 M | -20.3 M | -37.3 M | -11.9 M | 1.25 M | -857 K | -2.34 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.25 M | -203 M | -37 M |
Quarterly Operating Income CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -246 K | -11.1 M | -13.4 M | - | -13.7 M | -7.33 M | -22.6 M | - | -28.8 M | -27.6 M | -24.3 M | - | -17.3 M | -21.7 M | -19.1 M | - | -8.73 M | -4.74 M | -858 K | - | -2.91 M | -10.8 M | -5.75 M | - | -6.75 M | -6.84 M | -5.4 M | - | -2.72 M | -5.21 M | -5.24 M | - | -3.86 M | -3.6 M | -8.54 M | - | -4.93 M | -6.97 M | -6.57 M | - | -3.19 M | -2.89 M | -1.39 M | - | 1.39 M | -345 K | -227 K | - | -332 K | -256 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.39 M | -28.8 M | -8.29 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 17.05 | -2.15 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
598 M | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.92 | -6.58 % | $ 338 M | Israel |
 |
Illumina
ILMN
|
-833 M | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 102.09 | 0.7 % | $ 12.5 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 105.26 | 4.46 % | $ 4.15 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.59 | -25.21 % | $ 115 K | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 6.86 | -2.63 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 17.81 | 2.24 % | $ 437 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
-334 M | $ 2.13 | -1.61 % | $ 540 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
-2.92 M | - | -1.84 % | $ 15.3 M | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 192.57 | -0.96 % | $ 9.89 B | USA |
 |
Quotient Limited
QTNT
|
-82.7 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
RadNet
RDNT
|
105 M | $ 75.0 | -4.65 % | $ 5.48 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 182.21 | 0.35 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 7.94 | -1.0 % | $ 1.03 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |